Rybrevant Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising incidence of non-small cell lung cancer, advancements in molecular diagnostics, increased approval of targeted cancer drugs, expansion of oncology specialty centers, clinical validation of EGFR-targeted therapies.

The growth in the forecast period can be attributed to increasing demand for personalized cancer treatment, expansion of genomic testing in oncology, growing investment in biologic drug development, rising adoption of combination cancer therapies, continued innovation in antibody-based treatments. Major trends in the forecast period include increasing adoption of targeted oncology therapies, rising use of monoclonal antibodies in lung cancer, growing focus on precision medicine approaches, expansion of biomarker-driven cancer treatments, enhanced development of combination oncology regimens.

The rising number of cancer patients is expected to drive the growth of the rybrevant market going forward. Cancer patients are individuals diagnosed with cancer, a broad group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The increase in the number of cancer patients is largely driven by an aging population, as cancer risk rises with age, along with advancements in diagnostic technologies that have improved early detection and reporting of cancer cases. Rybrevant is used in the treatment of non-small cell lung cancer by targeting the EGFR and MET proteins, particularly in patients with EGFR exon 20 insertion mutations, thereby inhibiting tumor growth and activating immune responses. For instance, in May 2024, according to the Canadian Cancer Society, a Canada-based national cancer charity, 32,100 people in Canada were diagnosed with lung cancer in 2024, accounting for 23.5% of all cancer-related deaths. Notably, lung cancer cases among females increased from 15,800 in 2023 to 17,300 in 2024. Therefore, the increasing number of cancer patients is driving the growth of the rybrevant market.

Major companies operating in the rybrevant market are concentrating on the development of innovative solutions, such as targeted therapies for non-small cell lung cancer (NSCLC), to address the growing demand for precision oncology, improved treatment effectiveness, and therapeutic options for patients with rare genetic mutations. Targeted therapies for NSCLC are advanced treatments that focus on specific molecular alterations within cancer cells, allowing precise inhibition of tumor growth while minimizing damage to healthy tissues. For instance, in March 2024, Johnson & Johnson Inc., a Canada-based pharmaceutical company, received approval from the FDA for Rybrevant (amivantamab-vmjw) as a first-line therapy for NSCLC patients with specific EGFR mutations. Rybrevant is a bispecific antibody treatment composed of engineered molecules that simultaneously target the EGFR and MET pathways, helping to block tumor progression, overcome resistance mechanisms, and improve overall survival outcomes. Compared to traditional chemotherapy, it provides mutation-specific activity, improved tolerability, and enhanced progression-free survival.

In April 2025, Janssen-Cilag, a Belgium-based pharmaceutical company, entered into a partnership with Halozyme Therapeutics to develop subcutaneous oncology formulations using ENHANZE technology. Through this collaboration, Janssen strengthens its strategic platform by enabling faster and more patient-friendly subcutaneous administration of RYBREVANT, reducing infusion times and potentially increasing adoption and accessibility. Halozyme Therapeutics is a U.S.-based company that provides proprietary drug delivery enzyme technology designed to facilitate the subcutaneous delivery of biologic therapies.

Major companies operating in the rybrevant market are Johnson & Johnson Service Inc.

North America was the largest region in the rybrevant market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rybrevant market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rybrevant market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the rybrevant market by increasing costs of imported monoclonal antibody drug substances, bioreactor components, sterile delivery systems, and specialty oncology distribution services. Oncology treatment centers in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces higher production input costs for antibody manufacturing. These tariffs contribute to higher therapy prices and reimbursement pressures. However, they are also encouraging domestic biologics manufacturing, regional antibody production facilities, and localized supply chains for advanced oncology treatments.

The rybrevant market research report is one of a series of new reports that provides rybrevant market statistics, including rybrevant industry global market size, regional shares, competitors with a rybrevant market share, detailed rybrevant market segments, market trends and opportunities, and any further data you may need to thrive in the rybrevant industry. This rybrevant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rybrevant (amivantamab) is a monoclonal antibody therapy used for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It functions by targeting and inhibiting the EGFR and MET receptors, thereby helping to slow tumor growth and disease progression.

The primary clinical indications for Rybrevant include non-small cell lung cancer (NSCLC) with MET amplification, broader EGFR-mutated NSCLC, and its use in combination therapies for advanced or metastatic NSCLC. Non-small cell lung cancer with MET amplification describes a subgroup of NSCLC characterized by an increased number of MET gene copies. The MET gene encodes the hepatocyte growth factor receptor (HGFR), which is involved in cancer cell proliferation, metastasis, and resistance to treatment. The various treatment lines include first-line and second-line therapy, as well as monotherapy for NSCLC with EGFR mutations. The routes of administration include intravenous infusion and subcutaneous injection, and the drug is distributed through multiple channels such as hospitals and specialty pharmacies.

The rybrevant market consists of sales of products including targeted therapy drugs, immunotherapy drugs, chemotherapy drugs, and angiogenesis inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.